

Investor service announcement no. 3/2016

To: NASDAQ OMX Copenhagen

Hørsholm, Denmark, 11 May, 2016

Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2016 – results from 1 January to 31 March, 2016

Veloxis Pharmaceuticals A/S (OMX: VELO) will announce the Interim Report for the first Quarter 2016 on Wednesday 18 May, 2016 after 05:00 PM CET. Veloxis' Management will host an accompanying conference call to discuss the financial results on Thursday 19 May, 2016 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EST (New York),

To access the live conference call, please dial one of the following numbers:

+45 32 71 16 59 (Denmark)

+44 (0) 20 3427 1910 (UK)

+1 646 254 3362 (USA)

Access code 8446996

Following the conference call, a recording will be available on the company's website <http://www.veloxis.com>.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Craig A. Collard

President & CEO

Phone: +1 919 524 4317

Email: cac@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with offices in New Jersey and North Carolina, U.S.A., Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ Copenhagen under the trading symbol NASDAQ: VELO.

For further information, please visit www.veloxis.com.